Triastek and BioNTech Partner to Develop 3D-Printed Oral RNA Therapeutics in $1.2 Billion Deal
核心洞察
Triastek (搜索) and BioNTech have entered a research partnership to develop 3D-printed oral RNA therapeutics (搜索) using advanced tablet designs that optimize delivery across the gastrointestinal mucosa (搜索).
The collaboration leverages Triastek (搜索)'s 3D Microstructure for Oral Peptide (3D μS-OR) technology to create multi-layer and multi-compartment tablet structures that minimize RNA degradation in the gastrointestinal tract.
Under the agreement terms, Triastek (搜索) receives $10 million upfront with potential milestone payments exceeding $1.2 billion plus tiered royalties on future product sales.
BioNTech and Triastek (搜索) have announced a research partnership and platform technology license agreement to develop 3D-printed oral RNA therapeutics (搜索), marking a significant advancement in the delivery of large molecule drugs. The collaboration combines BioNTech's expertise in next-generation immunotherapy with Triastek's innovative 3D printing capabilities to create oral formulations of RNA therapeutics.
Novel 3D Printing Technology Platform
The partnership centers on Triastek (搜索)'s 3D Microstructure for Oral Peptide (3D μS-OR) technology, which the company describes as its "most challenging technology to date." This platform enables the creation of tablet designs with distinct external and internal geometries, including multiple-layer and multi-compartment structures that are specifically engineered to optimize RNA therapeutic delivery.
The 3D printing approach addresses critical challenges in oral RNA delivery by minimizing degradation in the gastrointestinal tract and ensuring therapeutics reach areas where absorption potential is highest. The technology optimizes delivery across the gastrointestinal mucosa (搜索), a significant hurdle in developing oral formulations of traditionally injectable RNA therapeutics (搜索).
Strategic Partnership Terms
Under the agreement, Triastek (搜索) is entitled to receive an upfront payment of $10 million, with additional development, regulatory, and commercial milestone payments that could exceed $1.2 billion. The company will also receive tiered royalties on potential future product sales from BioNTech.
"We are immensely honoured to announce our collaboration with BioNTech, a leader in revolutionising patient care with transformative medicines," stated Dr. Senping Cheng, Founder and CEO of Triastek (搜索). "We believe this collaboration stands as a promising milestone in advancing oral RNA therapeutics (搜索) using 3D printing technology and aims to set new benchmarks in the development of large molecule oral drugs."
Therapeutic Applications and Market Impact
BioNTech specializes in next-generation immunotherapy, including novel therapies for cancer (搜索) and other serious diseases. The collaboration aims to provide groundbreaking therapies in an easy-to-administer tablet formulation, potentially transforming how RNA therapeutics (搜索) are delivered to patients.
The partnership represents a significant step forward in addressing the challenge of oral delivery for large molecule drugs, which have traditionally required injection due to stability and absorption issues. By leveraging 3D printing technology, the companies aim to create oral formulations that maintain therapeutic efficacy while improving patient convenience and compliance.